Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Lisa A. Boardman

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1330-2054; OpenAlex author ID A5029881354, A5135450721. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
32
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: 1 paper · 2016: none · 2017: 2 papers · 2018: none · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 8

  1. Pancreatic cancer surveillance not recommended for familial adenomatous polyposis: a fine and gray risk analysis. Co-author DOI 10.1007/s10689-025-00512-5↗
  2. Shorter Treatment-Naïve Leukocyte Telomere Length is Associated with Poorer Overall Survival of Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1055-9965.epi-20-1279↗
  3. Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study. Co-author DOI 10.14309/ctg.0000000000000414↗
  4. Leukocyte Telomere Length and Its Interaction with Germline Variation in Telomere-Related Genes in Relation to Pancreatic Adenocarcinoma Risk. Co-author DOI 10.1158/1055-9965.epi-19-1597↗
  5. Genetically Predicted Telomere Length is not Associated with Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-17-0100↗
  6. Telomere Length and Pancreatic Cancer Risk-Reply. First author DOI 10.1158/1055-9965.epi-17-0307↗
  7. New DNA Methylation Markers for Pancreatic Cancer: Discovery, Tissue Validation, and Pilot Testing in Pancreatic Juice. Co-author DOI 10.1158/1078-0432.ccr-14-2469↗
  8. Telomere length and pancreatic cancer: a case-control study. Last author DOI 10.1158/1055-9965.epi-12-0671↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gloria M. Petersen · 6 shared papers, 2012–2021 · strength 0.50
  2. Samuel O. Antwi · 4 shared papers, 2017–2021 · strength 0.42
  3. Aminah Jatoi · 3 shared papers, 2017–2021 · strength 0.31
  4. Kari G. Rabe · 3 shared papers, 2017–2021 · strength 0.31
  5. Ann L. Oberg · 3 shared papers, 2017–2021 · strength 0.31
  6. Douglas L. Riegert‐Johnson · 2 shared papers, 2021–2025 · strength 0.30
  7. Hugues Sicotte · 2 shared papers, 2020–2021 · strength 0.23
  8. Jewel N Samadder · 1 shared paper, 2025 · strength 0.20
  9. Aleksander M. Bogdanski · 1 shared paper, 2025 · strength 0.20
  10. Jeanin Elise van Hooft · 1 shared paper, 2025 · strength 0.20
  11. Lydia G. van der Geest · 1 shared paper, 2025 · strength 0.20
  12. Bert A. Bonsing · 1 shared paper, 2025 · strength 0.20
  13. Monique Esther van Leerdam · 1 shared paper, 2025 · strength 0.20
  14. Lodewijk A.A. Brosens · 1 shared paper, 2025 · strength 0.20
  15. Derk C.F. Klatte · 1 shared paper, 2025 · strength 0.20
  16. Michael B. Wallace · 1 shared paper, 2025 · strength 0.20
  17. Amit Mahipal · 1 shared paper, 2021 · strength 0.13
  18. Douglas O. Faigel · 1 shared paper, 2021 · strength 0.11
  19. Mitesh J. Borad · 1 shared paper, 2021 · strength 0.11
  20. Niloy Jewel Samadder · 1 shared paper, 2021 · strength 0.11
  21. Rahul Pannala · 1 shared paper, 2021 · strength 0.11
  22. Daniel H. Ahn · 1 shared paper, 2021 · strength 0.11
  23. Mohamad Bassam Sonbol · 1 shared paper, 2021 · strength 0.11
  24. Tanios Bekaii‐Saab · 1 shared paper, 2021 · strength 0.11
  25. Pedro Luiz Serrano Usón · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.